Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radotinib Versus Imatinib in Newly Diagnosed Ph+ CML-CP
NCT03722420Phase 3Active, not recruiting
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Dec 2018
- Primary completion
- Mar 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of radotinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Il-Yang Pharmaceutical. Primary endpoint: Major Molecular Response at 12 months. Started Dec 2018; status: active, not recruiting.
02
Drugs
radotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03722420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722420.